Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 3/20 | 0.53 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 3/20 | 0.53 |
| ▸ | HTR2A known ✓ | P28223 | 2/20 | 0.53 |
| ▸ | SLC6A4 known ✓ | P31645 | 2/20 | 0.53 |
| ▸ | KCNH2 known ✓ | Q12809 | 2/20 | 0.53 |
| ▸ | ADRA2A known ✓ | P08913 | 2/20 | 0.53 |
| ▸ | DRD2 known ✓ | P14416 | 1/20 | 0.53 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.53 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.53 |
| ▸ | OPRK1 known ✓ | P41145 | 1/20 | 0.53 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.53 |
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.74 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.74 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.74 |
| ▸ | LMNA | P02545 | 6/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.67 |
| ▸ | NPY1R | P25929 | 1/20 | 0.67 |
| ▸ | NPY2R | P49146 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2278072 | 1.00 | CYP2D6 (0.74) | CYP2D6CYP2C19CYP1A2LMNAALDH1A1 | |
| Hydrochloric Acid SCHEMBL11774931 | 0.98 | CYP2D6 (0.71) | CYP2D6CYP2C19CYP1A2LMNAALDH1A1 | |
| SCHEMBL820553 | 0.98 | CYP2D6 (0.77) | CYP2D6CYP2C19CYP1A2LMNAALDH1A1 | |
| SCHEMBL31316173 | 0.98 | CYP2D6 (0.77) | CYP2D6CYP2C19CYP1A2LMNAALDH1A1 | |
| SCHEMBL2142323 | 0.96 | CYP2D6 (0.74) | CYP2D6CYP2C19CYP1A2LMNAALDH1A1 | |
| SCHEMBL10932466 | 0.85 | CYP2D6 (1.00) | CYP2D6CYP2C19CYP1A2LMNAALDH1A1 | |
| SCHEMBL1977209 | 0.84 | CYP2D6 (0.56) | CYP2D6CYP2C19CYP1A2LMNAALDH1A1 | |
| SCHEMBL18773886 | 0.82 | CYP2D6 (0.71) | CYP2D6CYP2C19CYP1A2LMNAALDH1A1 | |
| SCHEMBL13381683 | 0.81 | CYP2D6 (0.76) | CYP2D6CYP2C19CYP1A2LMNAALDH1A1 | |
| SCHEMBL4818483 | 0.81 | CYP2D6 (0.65) | CYP2D6CYP2C19CYP1A2LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1963 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11717481-B2 | Reduction of flake-like aggregation in nanoparticulate active agent compositions | ALKERMES PHARMA IRELAND LIMITED (IE) | 2023-08-08 | — | — | US | claimed |
| US-20220211626-A1 | REDUCTION OF FLAKE-LIKE AGGREGATION IN NANOPARTICULATE ACTIVE AGENT COMPOSITIONS | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2022-07-07 | — | — | US | claimed |
| US-11253478-B2 | Reduction of flake-like aggregation in nanoparticulate active agent compositions | ALKERMES PHARMA IRELAND LIMITED (IE) | 2022-02-22 | — | — | US | claimed |
| EP-3536773-B1 | METHOD OF MINIMIZING ENZYME BASED AEROSOL MIST USING A PRESSURE SPRAY SYSTEM | ECOLAB USA INC (US) | 2021-09-29 | — | — | EP | claimed |
| EP-3755148-A1 | NANOSUSPENSIONS OF SALSALATE AND METHODS OF USING THE SAME | RHNanoPharma (US) | 2020-12-30 | — | — | EP | claimed |
| US-20200390737-A1 | NANOSUSPENSIONS OF SALSALATE AND METHODS OF USING THE SAME | RHNANOPHARMA (US) | 2020-12-17 | — | — | US | claimed |
| US-10683472-B2 | Method of minimizing enzyme based aerosol mist using a pressure spray system | ECOLAB USA INC. (US) | 2020-06-16 | — | — | US | claimed |
| WO-2020065541-A1 | MICROEMULSIONS AND METHODS OF USE | MOROCCANOIL ISRAEL, LTD. (IL) | 2020-04-02 | — | — | WO | claimed |
| EP-3536773-A1 | METHOD OF MINIMIZING ENZYME BASED AEROSOL MIST USING A PRESSURE SPRAY SYSTEM | Ecolab USA Inc. (US) | 2019-09-11 | — | — | EP | claimed |
| WO-2019165240-A1 | NANOSUSPENSIONS OF SALSALATE AND METHODS OF USING THE SAME | RHNANOPHARMA (US) | 2019-08-29 | — | — | WO | claimed |
| WO-2003080024-A2 | NANOPARTICULATE COMPOSITIONS OF MAP KINASE INHIBITORS | ELAN PHARMA INTERNATIONAL, LTD. (IE) | 2003-10-02 | — | — | WO | claimed |
| WO-2003080023-A2 | FAST DISSOLVING DOSAGE FORMS HAVING REDUCED FRIABILITY | ELAN PHARMA INTERNATIONAL LIMITED (IE) | 2003-10-02 | — | — | WO | claimed |
| WO-2003080027-A1 | NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS | ELAN PHARMA INTERNATIONAL, LTD. (IE) | 2003-10-02 | — | — | WO | claimed |
| US-20030181411-A1 | Contacting and adsorbing an insoluble enzyme inhibitor with a surface stabilizer | ELAN PHARMA INTERNATIONAL LTD. | 2003-09-25 | — | — | US | claimed |
| WO-2003066021-A2 | DRUG NANOPARTICLES WITH LYSOZYME SURFACE STABILISER | ELAN PHARMA INTERNATIONAL, LTD. (IE) | 2003-08-14 | — | — | WO | claimed |
| US-20030137067-A1 | Compositions having a combination of immediate release and controlled release characteristics | ELAN PHARMA INTERNATIONAL LTD. | 2003-07-24 | — | — | US | claimed |
| US-20030095928-A1 | Nanoparticulate insulin | ELAN PHARMA INTERNATIONAL LIMITED | 2003-05-22 | — | — | US | claimed |
| WO-2003030872-A2 | COMPOSITIONS HAVING A COMBINATION OF PARTICLES FOR IMMEDIATE RELEASE AND FOR CONTROLLED RELEASE | ELAN PHARMA INTERNATIONAL LTD. (IE) | 2003-04-17 | — | — | WO | claimed |
| WO-2003024425-A1 | NANOPARTICULATE INSULIN FORMULATIONS | ELAN PHARMA INTERNATIONAL, LTD. (IE) | 2003-03-27 | — | — | WO | claimed |
| US-5622708-A | Erodible sanitizing caulk | ECOLAB INC. (US) | 1997-04-22 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200390737-A1 | NANOSUSPENSIONS OF SALSALATE AND METHODS OF USING THE SAME | TUBAL3, TUBB6, TUBA1A | SLC6A2 825/4885SIGMAR1 1253/4885HTR2A 2158/4885 |
| US-20030181411-A1 | Contacting and adsorbing an insoluble enzyme inhibitor with a surface stabilizer | PACSIN2, MAP3K20, MAP3K2 | SLC6A2 2874/4885SIGMAR1 2060/4885HTR2A 4509/4885 |
| US-20030137067-A1 | Compositions having a combination of immediate release and controlled release characteristics | NAPA, CD63, RPL36 | SLC6A2 773/4885SIGMAR1 259/4885HTR2A 293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.